Queen Mary University of London has been ranked in the top 100 universities in the world in the 2015/16 Times Higher Education World University Rankings:

https://www.timeshighereducation.com/world-university-rankings/queen-mary-university-of-london?ranking-dataset=133819

The rankings also put us in the following categories:

Top 10% in international outlook in 2016
Top 20% in research in 2016
Top 10% in citations in 2016
 

The Times Higher Education World University Ranking is one of the most respected league tables in the world. It takes into account teaching, research, citations, international outlook and industry income.

President and Principal of Queen Mary, Professor Simon Gaskell, said: “Our remarkable rise up the rankings in such a short space of time is testament to the calibre of the academic and professional services staff at QMUL and demonstrates our continued ambition to improve our teaching and research.”

QMUL has been rising rapidly up World University Ranking, jumping nearly fifty places in just three years from 145th in 2012.

In particular QMUL was praised for its international outlook where it ranks in the top 10 per cent worldwide.

Professor Gaskell, continued: “We are proud of our ability to attract and nurture the best students and staff regardless of their background. Our strong links with universities and academics from around the world allow our students both from here in the UK and elsewhere to take a full part in a modern global community.”

Two Blizard Institute Researchers Awarded Young Investigator Awards by the International Society for Chemotherapy and Cancer

Jonathan Betts (Postdoctoral Research Assistant) and Lynette Phee (Honorary Clinical Lecturer), members of David Wareham’s group in the Centre for Immunobiology  have  been awarded Young Investigator Awards by the International Society for Chemotherapy and Cancer. This will enable them to present their work at the joint 2015 ICAAC/ICC conference in San Diego in September. ICAAC is the largest annual international meeting on antimicrobial resistance, chemotherapy and clinical infectious diseases with 2000 scientific presentations attended by more than 12,000 delegates. The ICC supports travel, accommodation and registration for a maximum of 10 early career researchers, following review of the quality, innovation and impact of the research submitted. Both Jonathan and Lynette received individual awards for work on the treatment of multi-drug resistant Gram-negative infections - outlined below. A link to all researchers successful in the ICC Young Investigator competition is available here

http://www.ischemo.org/awards/young-investigator-travel-awards

Jonathan Betts

Jonathan was born in 1981. He completed his PhD in Chemistry/Microbiology at the University of Hull currently a postdoctoral research scientist at Queen Mary, University of London.  Jonathan won this award for his abstract ‘In-vitro And In-vivo Activity Of ML302F A Novel Thioenolate Metallo-β-lactamase Inhibitor'

Lynette Phee

Lynette was born in 1981 and is currently a 4th year Specialist Trainee registrar in Clinical Microbiology with Barts Health / Homerton University Hospital NHS Trusts in London as well as a 2nd year PhD student with Queen Mary University of London.  Lynette won this award for her abstract ‘In Vitro and In Vivo Activity of Lactivicin Derivatives against Enterobacteriaceae Producing Extended-spectrum (ESBL) and Carbapenem hydrolysing β-lactamases’

Andy Prendergast from the Centre for Genomics and Child Health has been awarded a five-year Wellcome Trust Senior Clinical Fellowship to continue work he is undertaking in Zimbabwe on malnutrition.  His group is exploring interventions to prevent stunting in childhood - an often overlooked form of chronic malnutrition which increases mortality from infections and impairs long-term child development.  His current work on the SHINE trial is evalauting the independent and combined effects of improving water/hygiene/sanitation or infant feeding on stunting.  In his Senior Fellowship, Andy has been awarded £2M from the Wellcome Trust to undertake a trial to evaluate the impact of the antibiotic cotrimoxazole on birth outcomes and growth in rural Zimbabwe.  Antenatal women will be randomized to cotrimoxazole or placebo to see whether antibiotics reduces prematurity and increase birth weight, then infants will be randomized to cotrimoxazole or placebo to evaluate the impact of antibiotics on linear growth by 6 months.  Specimens will be collected from mothers and infants to explore the impact of antibiotics on inflammation, immune function, intestinal inflammation and the microbiota, in laboratory work to be undertaken in Zimbabwe and at the Blizard Institute.